Document is current
Any future updates will be listed below
-
Authors
Kenny, Grace http://orcid.org/0000-0002-9646-7910
O’Reilly, Sophie http://orcid.org/0000-0001-5546-7984
Wrigley Kelly, Neil
Negi, Riya
Gaillard, Colette http://orcid.org/0000-0002-7064-2530
Alalwan, Dana
Saini, Gurvin
Alrawahneh, Tamara
Francois, Nathan
Angeliadis, Matthew
Garcia Leon, Alejandro Abner
Tinago, Willard
Feeney, Eoin R.
Cotter, Aoife G.
de Barra, Eoghan
Yousif, Obada
Horgan, Mary
Doran, Peter
Stemler, Jannik
Koehler, Philipp http://orcid.org/0000-0002-7386-7495
Cox, Rebecca Jane http://orcid.org/0000-0002-8341-4078
O’Shea, Donal
Olesen, Ole F.
Landay, Alan
Hogan, Andrew E. http://orcid.org/0000-0001-5875-230X
Lelievre, Jean-Daniel
Gautier, Virginie
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Mallon, Patrick W. G.
,
Leon, Alejandro Garcia
Feeney, Eoin
de Barra, Eoghan
,
Mallon, Patrick
-
Funding
Funding for this research was provided by:
United States embassy in Ireland, no grant number.
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 19 October 2023
First Online: 2 November 2023
Competing interests
: E.F. has received consulting fees from Gilead, ViiV and Vidacare Ireland, and has been awarded a grant from Science Foundation Ireland outside the submitted work. E.d.B. has received consulting fees from Sanofi Pasteur and an honoraria/travel grant from Pfizer. P.M. has received honoraria and/or travel grants from Gilead Sciences, MSD, Astrazeneca, and ViiV Healthcare, and has been awarded grants by Science Foundation Ireland outside the submitted work. P.K. reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, Mundipharma Research Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., Datamed GmbH, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia GmbH, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC, streamedup! GmbH and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Research Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. J.S. has received research support from the German Federal Ministry of Education and Research (BMBF) and Basilea Pharmaceuticals Inc.; has received speaker honoraria by Pfizer Inc., Gilead, and AbbVie; has been a consultant to Gilead, Produkt&Markt GmbH, Alvea Vax. and Micron Research and has received travel grants by German Society for Infectious Diseases (DGI e.V.) and Meta-Alexander Foundation. O.A.C. reports grants or contracts from BMBF, Cidara, EU-DG RTD (101037867), Pfizer; Consulting fees from Biocon, Biosys, Janssen, Noxxon, Pfizer; Honoraria for lectures from Gilead, MedScape, Merck/MSD, Pfizer; Participation on a Data Safety Monitoring Board or Advisory Board from Cidara, Janssen. A.L. receives consulting fees from Abbott and is co-chair of the Gilead Research Scholars Programme. All other authors declare no competing interests.
